- PR Newswire•5 days ago
Alere Launches the Alere™ Malaria Ag P.f, the First-Ever Rapid Test to Screen Malaria Infection in Asymptomatic Individuals
WALTHAM, Mass., April 25, 2017 /PRNewswire/ -- Alere Inc. (ALR), a global leader in rapid diagnostics, today announced the launch of its Alere™ Malaria Ag P.f, a major technological breakthrough in high-sensitivity rapid testing versus currently available malaria RDTs (rapid diagnostic tests). The Alere Malaria Ag P.f offers a greater than tenfold improvement in the detection of histidine rich protein II (HRP-II) antigen of Plasmodium falciparum, which will enable better identification of individuals with very low parasitemia, many of whom may be without evident symptoms of malaria infection. This highly sensitive diagnostic will help healthcare workers screen individuals who are asymptomatic but may be carrying the parasite, and thus can aid the implementation of surveillance and mass screen-and-treat programs that are critical for accelerating malaria elimination.
- Reuters•10 days ago
US drug distributor Cardinal Health Inc’s deal to buy Medtronic Plc’s medical supplies units days after Abbott Laboratories agreed to a long-awaited purchase of diagnostic testing company Alere Inc has raised the pulse of a sector suppressed by potential healthcare policy upheaval. Highly anticipated tax reforms are being delayed by the ongoing healthcare policy debate.
- TheStreet.com•11 days ago
Troubles at a plant acquired with St. Jude and continuing risks to closing the Alere deal linger over M&A spree.
ALR : Summary for Alere Inc. - Yahoo Finance
Alere Inc. (ALR)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||49.06 - 49.24|
|52 Week Range||31.47 - 49.42|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-70.14|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|